Drugs Similar to L-DOPA

USES: • For the temporary relief of symptoms including: • stiff muscles • tremor • weakness • fatigue These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

USES: • For the temporary relief of symptoms including: • stiff muscles • tremor • weakness • fatigue These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

INDICATIONS For the temporary relief of anxiousness, weakness, fatigue, hay fever, or congestion due to sensitivity to phenolic compounds found in foods or other products.*

INDICATIONS: For temporary relief of anxiety, chest congestion with constriction, disorientation, shakiness, hay fever, and hives

INDICATIONS: May temporarily relieve symptoms associated with reactions to L-Dopa.** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.

USES: • For the temporary relief of symptoms including: • neurological support • pain • joint pain • swelling These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

Carbidopa and levodopa extended-release tablets, USP are an extended-release combination of carbidopa and levodopa for the treatment of Parkinson's disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and levodopa extended-release tablets, USP are supplied as extended-release tablets containing either 25 mg of carbidopa and 100 mg of levodopa, or 50 mg of carbidopa and 200 mg of levodopa. Inactive ingredients are hydroxypropyl cellulose, magnesium stearate, hypromellose and also contain FD&C Blue #2. The 25 mg/100 mg tablet is supplied as a light blue, mottled, oval, uncoated tablets debossed with 'SG' on one side and '460' on the other side. The 50 mg/200 mg tablet is supplied as a light blue, mottled, oval, uncoated tablets debossed with 'SG' on one side and '461' on the other side. Carbidopa and levodopa extended-release tablets, USP are polymeric-based drug delivery system that controls the release of carbidopa and levodopa as it slowly erodes. Carbidopa and levodopa extended-release tablet 25 mg/100 mg is available to facilitate titration when 100 mg steps are required. FDA approved dissolution test specifications differ from USP.

Carbidopa and levodopa tablets, USP are a combination product for the treatment of Parkinson's disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and Levodopa Tablets, USP for oral administration, are supplied in three strengths: 10 mg/100 mg, containing 10 mg of carbidopa, USP and 100 mg of levodopa, USP. 25 mg/100 mg, containing 25 mg of carbidopa, USP and 100 mg of levodopa, USP. 25 mg/250 mg, containing 25 mg of carbidopa, USP and 250 mg of levodopa, USP. In addition, each tablet contains the following inactive ingredients: corn starch, magnesium stearate, microcrystalline cellulose, pregelatinized starch (maize). In addition, the 25 mg/100 mg strength contain D&C yellow #10 aluminum lake and FD&C yellow #6 aluminum lake (sunset yellow lake). The 10 mg/100 mg and 25 mg/250 mg strengths contain FD&C blue #2 aluminum lake. 67944b5f-figure-01 67944b5f-figure-02

Carbidopa and Levodopa tablet, USP is a combination of carbidopa and levodopa for the treatment of Parkinson's disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 ∙H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and Levodopa is supplied as tablets in three strengths: Carbidopa and Levodopa tablets, USP 10 mg/100 mg, containing 10 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa tablets, USP 25 mg/100 mg, containing 25 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa tablets, USP 25 mg/250 mg, containing 25 mg of carbidopa and 250 mg of levodopa. Inactive ingredients are hydroxypropyl cellulose, pregelatinized starch, crospovidone, microcrystalline cellulose, and magnesium stearate. Carbidopa and levodopa tablets, USP 10 mg/100 mg and 25 mg/250 mg also contain FD&C Blue #2. Carbidopa and levodopa tablets, USP 25 mg/100 mg also contain D&C Yellow #10. Chemical Structure Chemical Structure

Carbidopa and levodopa tablet, USP is a combination of carbidopa and levodopa for the treatment of Parkinson’s disease and syndrome. Carbidopa USP, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa USP, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 and its structural formula is: Carbidopa and levodopa is supplied as tablets in three strengths: Carbidopa and levodopa tablets, USP, 25 mg/100 mg, containing 25 mg of carbidopa and 100 mg of levodopa. Carbidopa and levodopa tablets, USP, 10 mg/100 mg, containing 10 mg of carbidopa and 100 mg of levodopa. Carbidopa and levodopa tablets, USP, 25 mg/250 mg, containing 25 mg of carbidopa and 250 mg of levodopa. Inactive ingredients are microcrystalline cellulose, corn starch, pregelatinized maize starch, sodium starch glycolate, magnesium stearate. Carbidopa and levodopa tablets, USP 10 mg/100 mg and 25 mg/250 mg also contain FD&C Blue 2. Carbidopa and levodopa tablets, USP 25 mg/100 mg also contain D&C Yellow 10 and FD&C Yellow 6. FDA approved dissolution method differs from that of the USP.

Carbidopa and levodopa tablets, USP are a combination product for the treatment of Parkinson's disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and Levodopa Tablets, USP for oral administration, are supplied in three strengths: 10 mg/100 mg, containing 10 mg of carbidopa, USP and 100 mg of levodopa, USP. 25 mg/100 mg, containing 25 mg of carbidopa, USP and 100 mg of levodopa, USP. 25 mg/250 mg, containing 25 mg of carbidopa, USP and 250 mg of levodopa, USP. In addition, each tablet contains the following inactive ingredients: corn starch, magnesium stearate, microcrystalline cellulose, pregelatinized starch (maize). In addition, the 25 mg/100 mg strength contain D&C yellow #10 aluminum lake and FD&C yellow #6 aluminum lake (sunset yellow lake). The 10 mg/100 mg and 25 mg/250 mg strengths contain FD&C blue #2 aluminum lake. 67944b5f-figure-01 67944b5f-figure-02

Carbidopa and levodopa extended-release tablets, USP are an extended-release combination of carbidopa and levodopa for the treatment of Parkinson’s disease and syndrome. Carbidopa, USP , an inhibitor of aromatic amino acid decarboxylation, is a white to creamy white, odorless or practically odorless powder, freely soluble in 3N hydrochloric acid, slightly soluble in water and in methanol, practically insoluble in alcohol, in acetone, in chloroform and in ether, with a molecular weight of 244.24. It is designated chemically as (-)-L-α­hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its empirical formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.24. Levodopa, USP, an aromatic amino acid, is a white to off-white, odorless , crystalline powder, slightly soluble in water, freely soluble in 3N hydrochloric acid and insoluble in alcohol with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its empirical formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and levodopa extended-release tablets, USP are supplied as extended-release tablets containing either 25 mg of carbidopa and 100 mg of levodopa, or 50 mg of carbidopa and 200 mg of levodopa. Inactive ingredients are hydroxypropyl cellulose, magnesium stearate, and hypromellose. Carbidopa and levodopa extended-release tablets USP, 25 mg/100 mg and carbidopa and levodopa extended-release tablets USP, 50 mg/200 mg also contain FD&C Blue #2 Aluminium Lake and FD&C Red #40 Aluminium Lake. The 25 mg/100 mg tablet is supplied as an oval shaped mottled tablet that is dappled-purple in color and is debossed with “L519” on one side and plain on the other. The 50 mg/200 mg tablet is supplied as an oval shaped mottled tablet that is dappled-purple in color and is debossed with “L520” on one side and plain on the other. Carbidopa and levodopa extended-release tablets, USP are polymeric-based drug delivery system that controls the release of carbidopa and levodopa as it slowly erodes. Carbidopa and levodopa extended-release tablet 25 mg/100 mg is available to facilitate titration when 100 mg steps are required. FDA approved dissolution specifications differs from the USP dissolution specifications. Structure-Carbidopa Structure-Levodopa

Carbidopa and levodopa extended-release tablets, USP are an extended-release combination of carbidopa and levodopa for the treatment of Parkinson's disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and levodopa extended-release tablets, USP are supplied as extended-release tablets containing either 25 mg of carbidopa and 100 mg of levodopa, or 50 mg of carbidopa and 200 mg of levodopa. Inactive ingredients are hydroxypropyl cellulose, magnesium stearate, hypromellose and also contain FD&C Blue #2. The 25 mg/100 mg tablet is supplied as a light blue, mottled, oval, uncoated tablets debossed with 'SG' on one side and '460' on the other side. The 50 mg/200 mg tablet is supplied as a light blue, mottled, oval, uncoated tablets debossed with 'SG' on one side and '461' on the other side. Carbidopa and levodopa extended-release tablets, USP are polymeric-based drug delivery system that controls the release of carbidopa and levodopa as it slowly erodes. Carbidopa and levodopa extended-release tablet 25 mg/100 mg is available to facilitate titration when 100 mg steps are required. FDA approved dissolution test specifications differ from USP. Carbidopa Chemical Structure Levodopa Chemical Structure

Carbidopa and levodopa extended-release tablets, USP are extended-release combination of carbidopa and levodopa for the treatment of Parkinson’s disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white to creamy white, odorless or practically odorless powder, freely soluble in 3N hydrochloric acid; slightly soluble in water and in methanol; practically insoluble in alcohol, in acetone, in chloroform, and in ether, with a molecular weight of 244.24 g/mol. It is designated chemically as (-)-L-α- hydrazino-3,4-dihydroxy-α-methyldrocinnamic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.23 g/mol. Levodopa, USP an aromatic amino acid, is a white to off-white crystalline powder, freely soluble in 3N hydrochloric acid, slightly soluble in water and insoluble in alcohol, with a molecular weight of 197.19 g/mol. It is designated chemically as (2S)-2-Amino-3-(3,4-dihydroxyphenyl) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and levodopa extended-release tablets, USP are supplied as extended-release tablets containing either 50 mg of carbidopa and 200 mg of levodopa, or 25 mg of carbidopa and 100 mg of levodopa. Inactive ingredients: hydroxypropyl cellulose, lake blend purple (contains FD&C Red No. 40, FD &C Blue No. 2) and magnesium stearate. The 50 mg/200 mg tablets are supplied as purple, oval, convex tablets, debossed with “G” left of bisect on one side and “391” on the other side with mottled appearance. The 25 mg/100 mg tablets are supplied as purple, oval, convex tablets, debossed with “G” on one side and “392” on other side with mottled appearance. The carbidopa and levodopa extended-release tablets are polymeric-based drug delivery system that controls the release of carbidopa and levodopa as it slowly erodes. Carbidopa and levodopa extended-release tablet, 25 mg/100 mg is available to facilitate titration and as an alternative to the half-tablet of carbidopa and levodopa extended-release tablet, 50 mg/200 mg. Meets USP Dissolution Test 2. 1 1

Carbidopa and Levodopa tablet, USP is a combination of carbidopa and levodopa for the treatment of Parkinson's disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 ∙H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and Levodopa is supplied as tablets in three strengths: Carbidopa and Levodopa tablets, USP 10 mg/100 mg, containing 10 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa tablets, USP 25 mg/100 mg, containing 25 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa tablets, USP 25 mg/250 mg, containing 25 mg of carbidopa and 250 mg of levodopa. Inactive ingredients are hydroxypropyl cellulose, pregelatinized starch, crospovidone, microcrystalline cellulose, and magnesium stearate. Carbidopa and levodopa tablets, USP 10 mg/100 mg and 25 mg/250 mg also contain FD&C Blue #2. Carbidopa and levodopa tablets, USP 25 mg/100 mg also contain D&C Yellow #10. Chemical Structure Chemical Structure

Carbidopa and Levodopa tablet, USP is a combination of carbidopa and levodopa for the treatment of Parkinson’s disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4- dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and Levodopa is supplied as tablets in three strengths: Carbidopa and Levodopa tablets, USP 10 mg/100 mg, containing 10 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa tablets, USP 25 mg/100 mg, containing 25 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa tablets, USP 25 mg/250 mg, containing 25 mg of carbidopa and 250 mg of levodopa. Inactive ingredients are hydroxypropyl cellulose, pregelatinized starch, crospovidone, microcrystalline cellulose, and magnesium stearate. Carbidopa and levodopa tablets, USP 10 mg/100 mg and 25 mg/250 mg also contain FD&C Blue #2. Carbidopa and levodopa tablets, USP 25 mg/100 mg also contain D&C Yellow #10. Carbidopa Chemical Structure Levodopa Chemical Structure

Carbidopa and levodopa tablet, USP is a combination of carbidopa and levodopa for the treatment of Parkinson’s disease and syndrome. Carbidopa USP, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa USP, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 and its structural formula is: Carbidopa and levodopa is supplied as tablets in three strengths: Carbidopa and levodopa tablets, USP, 25 mg/100 mg, containing 25 mg of carbidopa and 100 mg of levodopa. Carbidopa and levodopa tablets, USP, 10 mg/100 mg, containing 10 mg of carbidopa and 100 mg of levodopa. Carbidopa and levodopa tablets, USP, 25 mg/250 mg, containing 25 mg of carbidopa and 250 mg of levodopa. Inactive ingredients are microcrystalline cellulose, corn starch, pregelatinized maize starch, sodium starch glycolate, magnesium stearate. Carbidopa and levodopa tablets, USP 10 mg/100 mg and 25 mg/250 mg also contain FD&C Blue 2. Carbidopa and levodopa tablets, USP 25 mg/100 mg also contain D&C Yellow 10 and FD&C Yellow 6. FDA approved dissolution method differs from that of the USP. cdld-structure-carbidopa cdld-structure-levodopa

Carbidopa and Levodopa Tablets, USP are a combination of carbidopa and levodopa for the treatment of Parkinson's disease and syndrome. Carbidopa USP, an inhibitor of aromatic amino acid decarboxylation, is a white to creamy white powder, slightly soluble in water, with a molecular weight of 244.2. It is designated chemically as (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.2. Levodopa USP, an aromatic amino acid, is a white to off-white crystalline powder, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (-)-3-(3,4-Dihydroxyphenyl)-L-alanine. Its molecular formula is C 9 H 11 NO 4 and its structural formula is: Carbidopa and Levodopa Tablets, USP are supplied as tablets in three strengths: Carbidopa and Levodopa Tablets USP, 10 mg/100 mg contains 10 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa Tablets USP, 25 mg/100 mg contains 25 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa Tablets USP, 25 mg/250 mg contains 25 mg of carbidopa and 250 mg of levodopa. Inactive ingredients are crospovidone, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose and pregelatinized starch (corn). In addition, the 10 mg/100 mg and 25 mg/250 mg tablets contain FD&C Blue No. 2 Aluminum Lake and the 25 mg/100 mg tablets contain D&C Yellow No. 10 Aluminum Lake. Carbidopa Structural Formula Levodopa Structural Formula

Carbidopa and Levodopa tablet, USP is a combination of carbidopa and levodopa for the treatment of Parkinson’s disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4- dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and Levodopa is supplied as tablets in three strengths: Carbidopa and Levodopa tablets, USP 10 mg/100 mg, containing 10 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa tablets, USP 25 mg/100 mg, containing 25 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa tablets, USP 25 mg/250 mg, containing 25 mg of carbidopa and 250 mg of levodopa. Inactive ingredients are hydroxypropyl cellulose, pregelatinized starch, crospovidone, microcrystalline cellulose, and magnesium stearate. Carbidopa and levodopa tablets, USP 10 mg/100 mg and 25 mg/250 mg also contain FD&C Blue #2. Carbidopa and levodopa tablets, USP 25 mg/100 mg also contain D&C Yellow #10. Carbidopa Chemical Structure Levodopa Chemical Structure

Carbidopa and levodopa tablets, USP are a combination product for the treatment of Parkinson's disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and Levodopa Tablets, USP for oral administration, are supplied in three strengths: 10 mg/100 mg, containing 10 mg of carbidopa, USP and 100 mg of levodopa, USP. 25 mg/100 mg, containing 25 mg of carbidopa, USP and 100 mg of levodopa, USP. 25 mg/250 mg, containing 25 mg of carbidopa, USP and 250 mg of levodopa, USP. In addition, each tablet contains the following inactive ingredients: corn starch, magnesium stearate, microcrystalline cellulose, pregelatinized starch (maize). In addition, the 25 mg/100 mg strength contain D&C yellow #10 aluminum lake and FD&C yellow #6 aluminum lake (sunset yellow lake). The 10 mg/100 mg and 25 mg/250 mg strengths contain FD&C blue #2 aluminum lake. 67944b5f-figure-01 67944b5f-figure-02

Carbidopa and levodopa tablets are a combination product for the treatment of Parkinson's disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3.. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its empirical formula is C 10 H 14 N 2 O 4 .H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its empirical formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and levodopa tablets, USP for oral administration, are supplied in three strengths: 10 mg/100 mg, containing 10 mg of carbidopa and 100 mg of levodopa. 25 mg/100 mg, containing 25 mg of carbidopa and 100 mg of levodopa. 25 mg/250 mg, containing 25 mg of carbidopa and 250 mg of levodopa. In addition, each tablet contains the following inactive ingredients: 10 mg/100 mg — Corn starch, FD&C blue #2 aluminum lake, magnesium stearate, microcrystalline cellulose, and pregelatinized starch (maize). 25 mg/100 mg — Corn starch, D&C yellow #10 aluminum lake, FD&C yellow #6 aluminum lake (sunset yellow lake), magnesium stearate, microcrystalline cellulose, and pregelatinized starch (maize). 25 mg/250 mg — Corn starch, FD&C blue #2 aluminum lake, magnesium stearate, microcrystalline cellulose, and pregelatinized starch (maize). chemical-structure chemical-structure

Carbidopa and levodopa extended-release tablets, USP are an extended-release combination of carbidopa and levodopa for the treatment of Parkinson’s disease and syndrome. Carbidopa, USP, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.25. It is designated chemically as (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.23. Levodopa, USP, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-3-(3,4-Dihydroxyphenyl)-L-alanine. Its molecular formula is C 9 H 11 NO 4 and its structural formula is: Each extended-release tablet, for oral administration, contains either 25 mg of carbidopa and 100 mg of levodopa or 50 mg of carbidopa and 200 mg of levodopa. In addition, each tablet contains the following inactive ingredients: FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, hydroxypropyl cellulose, hypromellose, and magnesium stearate. The 25 mg/100 mg tablets are purple, oval, unscored tablets debossed with MYLAN on one side of the tablet and 88 on the other side of the tablet. The 50 mg/200 mg tablets are purple, oval, scored tablets debossed with MYLAN on one side of the tablet and 9 to the left of the score and 4 to the right of the score on the other side of the tablet. Carbidopa and levodopa extended-release tablets are designed in a drug delivery system that controls the release of carbidopa and levodopa as the tablets slowly erode. The 25 mg/100 mg carbidopa and levodopa extended-release tablet is available to facilitate titration and as an alternative to the half-tablet of 50 mg/200 mg carbidopa and levodopa extended-release. FDA approved dissolution test specifications differ from USP. Carbidopa Structural Formula Levodopa Structural Formula

Carbidopa and levodopa tablets, USP are a combination product for the treatment of Parkinson's disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and Levodopa Tablets, USP for oral administration, are supplied in three strengths: 10 mg/100 mg, containing 10 mg of carbidopa, USP and 100 mg of levodopa, USP. 25 mg/100 mg, containing 25 mg of carbidopa, USP and 100 mg of levodopa, USP. 25 mg/250 mg, containing 25 mg of carbidopa, USP and 250 mg of levodopa, USP. In addition, each tablet contains the following inactive ingredients: corn starch, magnesium stearate, microcrystalline cellulose, pregelatinized starch (maize). In addition, the 25 mg/100 mg strength contain D&C yellow #10 aluminum lake and FD&C yellow #6 aluminum lake (sunset yellow lake). The 10 mg/100 mg and 25 mg/250 mg strengths contain FD&C blue #2 aluminum lake. 67944b5f-figure-01 67944b5f-figure-02

Carbidopa and levodopa tablet, USP is a combination of carbidopa and levodopa for the treatment of Parkinson’s disease and syndrome. Carbidopa USP, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa USP, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (-)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 and its structural formula is: Carbidopa and levodopa is supplied as tablets in three strengths: Carbidopa and levodopa tablets, USP, 25 mg/100 mg, containing 25 mg of carbidopa and 100 mg of levodopa. Carbidopa and levodopa tablets, USP, 10 mg/100 mg, containing 10 mg of carbidopa and 100 mg of levodopa. Carbidopa and levodopa tablets, USP, 25 mg/250 mg, containing 25 mg of carbidopa and 250 mg of levodopa. Inactive ingredients are microcrystalline cellulose, corn starch, pregelatinized maize starch, sodium starch glycolate, magnesium stearate. Carbidopa and levodopa tablets, USP 10 mg/100 mg and 25 mg/250 mg also contain FD&C Blue 2. Carbidopa and levodopa tablets, USP 25 mg/100 mg also contain D&C Yellow 10 and FD&C Yellow 6. FDA approved dissolution method differs from that of the USP.

Carbidopa and Levodopa tablet, USP is a combination of carbidopa and levodopa for the treatment of Parkinson’s disease and syndrome. Carbidopa, USP an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.24. It is designated chemically as (-)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C 10 H 14 N 2 O 4 •H 2 O, and its structural formula is: Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.23. Levodopa, USP an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.19. It is designated chemically as (-)-L-α-amino-β-(3,4- dihydroxybenzene) propanoic acid. Its molecular formula is C 9 H 11 NO 4 , and its structural formula is: Carbidopa and Levodopa is supplied as tablets in three strengths: Carbidopa and Levodopa tablets, USP 10 mg/100 mg, containing 10 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa tablets, USP 25 mg/100 mg, containing 25 mg of carbidopa and 100 mg of levodopa. Carbidopa and Levodopa tablets, USP 25 mg/250 mg, containing 25 mg of carbidopa and 250 mg of levodopa. Inactive ingredients are hydroxypropyl cellulose, pregelatinized starch, crospovidone, microcrystalline cellulose, and magnesium stearate. Carbidopa and levodopa tablets, USP 10 mg/100 mg and 25 mg/250 mg also contain FD&C Blue #2. Carbidopa and levodopa tablets, USP 25 mg/100 mg also contain D&C Yellow #10.

HOMEOPATHIC INDICATIONS: For the temporary relief of symptoms related to H. Pylori infection including upper abdominal pain or discomfort, loss of appetite, belching, nausea, vomiting and fatigue.** **These statements are based upon traditional homeopathic principles. They have not been reviewed by the Food and Drug Administration.

HOMEOPATHIC INDICATIONS: For the temporary relief of symptoms related to poor circulation, and low energy.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

INDICATIONS: Helps to hydrate throat in an aid to reduce food obstruction when used daily.

HOMEOPATHIC INDICATIONS: For temporary relief of symptoms related to lymphatic and spleen malfunction including lack of energy, lethargy, weakness and poor muscle tone, poor appetite and sense of taste, poor digestion, loose and watery stools, and poor concentration.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

INDICATIONS For the temporary relief of itchy or watery eyes, sneezing, sinus congestion, or occasional headache due to sensitivity to phenolic compounds found in foods or other products.*

HOMEOPATHIC INDICATIONS: For the temporarily relief of symptoms related to Lyme disease or other co-infections including joint pain, severe headaches, fever, severe muscle aches/pain, flu-like feelings of headache, stiff neck, muscle aches, and change in smell/taste, difficulty chewing, swallowing or speaking, hoarseness of vocal cord problems.** **These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration.

INDICATIONS Temporarily relieves feeling ungrounded or lost, selfishness, or difficulty in moving past earlier emotional upset or suppressed feelings.*

Uses Uses* According to homeopathic indications these ingredients provide temporary relief from symptoms such as: • Red swollen bumps on the eyelid • Itching, burning or swollen eyelids after serious causes have been ruled out by a physician. *These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration.

INDICATIONS Temporarily relieves sadness, grief, worry, stress, or agitation.*

Use: This product is a Homeopathic Dilution formulated to support the body's immunity for the temporary relief of allergies.

Uses For temporary relief of symptoms: itchy, watery eyes, sore throat, cough, runny nose, sneezing, congestion, headaches, hoarseness. Reference image: Southern.jpg

USES This Homeopathic product of natural source helps relieve fatigue, lethargy, insomnia, irritability and loss of concentration associated with jet lag.

Uses Temporary relief of abdominal discomfort, flatulence, diarrhea, constipation.

Uses Temporary relief of occasional numbness, irritability, tingling.

HOMEOPATHIC INDICATIONS: For temporary relief of symptoms related to heartburn and esophageal reflux.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

INDICATIONS: For temporary relief of exhaustion, vomiting, prostration, and metallic taste.

HOMEOPATHIC INDICATIONS: For temporary relief of symptoms related to upper respiratory infections including fever, cough and runny nose.** **These statements are based upon traditional homeopathic principles. They have not been reviewed by the Food and Drug Administration.

Uses Temporarily relieves symptoms contributing to: excessive appetite Constitutional tendency to gain fat Cravings for sweets and starches Water retention Overeating Ravenous hunger Excess weight Abdominal fat As per various homeopathic materia medicas. Claims based on traditional homeopathic practice, not accepted medical evidence. These uses have not been evaluated by the FDA, and product has not been clinically tested. Reference image:Appetite and Weight.jpg

HOMEOPATHIC INDICATIONS: For temporary relief of symptoms related to candida albicans infection including nausea, drowsiness, lethargy, confusion, vaginal discharge, food or fungi sensitivities, petrochemicals, mucous congestion and tinnitus.** **These statements are based upon traditional homeopathic principles. They have not been reviewed by the Food and Drug Administration.

HOMEOPATHIC INDICATIONS: For the temporary relief of symptoms related to trauma associated with a dental procedure including inflammation, swelling and pain.** **These statements are based upon traditional homeopathic principles. They have not been reviewed by the Food and Drug Administration.